The Food and Drug Administration placed a clinical hold on Solid Biosciences Inc.'s (Nasdaq: SLDB) Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy. The stock price crashed $16.99 to close at $9.32.
Clinical hold placed on Solid Biosciences' study
March 15, 2018 at 17:19 PM EDT